中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2008年
26期
1841-1845
,共5页
王燕%陆权%滕国良%Feistein S.Sheldon%Micheal F.Beers%Aron B.Fisher
王燕%陸權%滕國良%Feistein S.Sheldon%Micheal F.Beers%Aron B.Fisher
왕연%륙권%등국량%Feistein S.Sheldon%Micheal F.Beers%Aron B.Fisher
腺病毒科%基因疗法%呼吸窘迫综合征,成人
腺病毒科%基因療法%呼吸窘迫綜閤徵,成人
선병독과%기인요법%호흡군박종합정,성인
Adenoviridae%Gene therapy%Respiratory distress syndrome,adult
目的 评价腺病毒自身的致炎作用在以其为载体的基因治疗中,对小鼠急性肺损伤(ALI)治疗效果的影响及意义.方法 C57/B6雄性小鼠随机分为4组:(1)以腺病毒为载体的靶基因LacZ治疗组(AdLacZ组):43只;(2)3个对照组:①O2吸入前组(Con组):26只;②O2吸人后组:TBS+磷酸盐缓冲液(PBS)治疗组(PBS组)36只;③无治疗对照组(无治疗组):33只.100%O2吸入诱导小鼠高氧性ALI动物模型;在100%O2吸入前48 h经鼻腔通道给予装载LaeZ DNA的腺病毒质粒感染小鼠,并观察小鼠的死亡率.B-半乳糖酶活性测定法用于确定转染的1acZ基因在肺脏的蛋白活性的表达水平;肺的干/湿重比、支气管-肺泡灌洗液内的蛋白浓度和细胞分类分析用于评价肺炎症反应的程度.结果 经鼻腔通路的以腺病毒为载体的基因治疗,可造成转染基因LacZ的蛋白表达活性在肺脏持续有效地高表达,而且其表达水平在O2吸人72 h后仍可维持为O:吸入前的2倍以上(3.688 U/mg v8 1.589 U/mg);该组小鼠对高氧吸入敏感性高于各对照组,50%的小鼠生存时间短于PBS组[(86±3)h vs(94±7)h];同时,该组小鼠的支气管-肺泡内炎症细胞的渗出在100%O2吸入48 h后明显高于各对照组,继续O2吸入24 h后明显下降约50%;肺干/湿重比和支气管-肺泡灌洗液内蛋白浓度无明显下降.结论 腺病毒自身的致炎作用对ALI基因治疗效果的影响是轻度和暂时的,但需在评价治疗效果时加以重视.
目的 評價腺病毒自身的緻炎作用在以其為載體的基因治療中,對小鼠急性肺損傷(ALI)治療效果的影響及意義.方法 C57/B6雄性小鼠隨機分為4組:(1)以腺病毒為載體的靶基因LacZ治療組(AdLacZ組):43隻;(2)3箇對照組:①O2吸入前組(Con組):26隻;②O2吸人後組:TBS+燐痠鹽緩遲液(PBS)治療組(PBS組)36隻;③無治療對照組(無治療組):33隻.100%O2吸入誘導小鼠高氧性ALI動物模型;在100%O2吸入前48 h經鼻腔通道給予裝載LaeZ DNA的腺病毒質粒感染小鼠,併觀察小鼠的死亡率.B-半乳糖酶活性測定法用于確定轉染的1acZ基因在肺髒的蛋白活性的錶達水平;肺的榦/濕重比、支氣管-肺泡灌洗液內的蛋白濃度和細胞分類分析用于評價肺炎癥反應的程度.結果 經鼻腔通路的以腺病毒為載體的基因治療,可造成轉染基因LacZ的蛋白錶達活性在肺髒持續有效地高錶達,而且其錶達水平在O2吸人72 h後仍可維持為O:吸入前的2倍以上(3.688 U/mg v8 1.589 U/mg);該組小鼠對高氧吸入敏感性高于各對照組,50%的小鼠生存時間短于PBS組[(86±3)h vs(94±7)h];同時,該組小鼠的支氣管-肺泡內炎癥細胞的滲齣在100%O2吸入48 h後明顯高于各對照組,繼續O2吸入24 h後明顯下降約50%;肺榦/濕重比和支氣管-肺泡灌洗液內蛋白濃度無明顯下降.結論 腺病毒自身的緻炎作用對ALI基因治療效果的影響是輕度和暫時的,但需在評價治療效果時加以重視.
목적 평개선병독자신적치염작용재이기위재체적기인치료중,대소서급성폐손상(ALI)치료효과적영향급의의.방법 C57/B6웅성소서수궤분위4조:(1)이선병독위재체적파기인LacZ치료조(AdLacZ조):43지;(2)3개대조조:①O2흡입전조(Con조):26지;②O2흡인후조:TBS+린산염완충액(PBS)치료조(PBS조)36지;③무치료대조조(무치료조):33지.100%O2흡입유도소서고양성ALI동물모형;재100%O2흡입전48 h경비강통도급여장재LaeZ DNA적선병독질립감염소서,병관찰소서적사망솔.B-반유당매활성측정법용우학정전염적1acZ기인재폐장적단백활성적표체수평;폐적간/습중비、지기관-폐포관세액내적단백농도화세포분류분석용우평개폐염증반응적정도.결과 경비강통로적이선병독위재체적기인치료,가조성전염기인LacZ적단백표체활성재폐장지속유효지고표체,이차기표체수평재O2흡인72 h후잉가유지위O:흡입전적2배이상(3.688 U/mg v8 1.589 U/mg);해조소서대고양흡입민감성고우각대조조,50%적소서생존시간단우PBS조[(86±3)h vs(94±7)h];동시,해조소서적지기관-폐포내염증세포적삼출재100%O2흡입48 h후명현고우각대조조,계속O2흡입24 h후명현하강약50%;폐간/습중비화지기관-폐포관세액내단백농도무명현하강.결론 선병독자신적치염작용대ALI기인치료효과적영향시경도화잠시적,단수재평개치료효과시가이중시.
Objective To evaluate the impact of endogenous inflammation caused by adenovims as a vector of gene therapy on monse model of acute lung injury(ALI).Methods black C57/B6 mice randomly divided into 4 research groups:(1)adenovirus encoded-lacZ genetreatment group(AdLacZ):n=AdLscZ reagent through intranasal administration to infect mice lungs at 48h before 100%O2 inhalation to induce ALI mouse model,which companied by mice survival rates recorded.B-gal protein activity in lung wag detected to show the level of LacZ DNA transgenic protein activity;meanwhile,the indices of lung wet/dry ratio and bronchial alveolar lavage liquid(BALF)analysis with protein concentration and cell elagsification were detected.Results The method of adenovirus-mediated gene therapy with intranagal administration restthed in IJacZ DNA transgenic protein activity to keep effective highly expression in lung.and the expression level maintained 2.fold increusing even after 72 h of O.inhalation compared to that before O2 inhalation(3.688 U/mg vs 1.589 U/mg);AdLacZ mice had more subjective to O2 inhalation compared to other groups.the 50%mice survival time of this group wag shorter compared to that of the PBS group [(86±3)h vs(94±7)h];also in AdLacZ group,the level of nucleated cell counting in BALF was statistically higher compared to other groups at 48 h of O2 inhalation,which following with 50%-level decreased within anther 24 h O2 inhalation;on the contrary,the level of lung wet/dry ratio and protein concentration in BALF didn,t show remarkably decreasing.Conclusion The endogenous inflammation caused by adenovirus as a vector in ALl gene therapy is temporary and rapidly weaken after getting a peak,however,enough attention still should be paid attention when evaluating the effect of gene therapy.